Ruxolitinib Improves Failure-Free and Overall Survival Versus Best Available Therapy in Steroid-Refractory Acute GVHD: Final 24‑Month REACH2 Analysis

Highlights

– In the randomized phase III REACH2 final analysis (24 months), ruxolitinib improved failure‑free survival compared with best available therapy (BAT) in steroid‑refractory acute graft‑versus‑host disease (SR‑aGVHD): median 4.86 versus 1.02 months (P < .001).

– Median overall survival (OS) and event‑free survival (EFS) favored ruxolitinib (OS 10.7 v 5.8 months; EFS 8.3 v 4.2 months).